

## NLG919

**Catalog #:** 27337-1

**Lot #:** 150724

**Size:** 10 mg


**Structure:**

**CAS Registry #:** 1402836-58-1

**Purity:** ≥98%

**Chemical Formula:** C<sub>18</sub>H<sub>22</sub>N<sub>2</sub>O

**Molecular Weight:** 282.4



**Description:** NLG919 is an orally available potent inhibitor of the indoleamine-(2,3)-dioxygenase (IDO) pathway, a crucial pathway involved in allergic inflammation that mediates immunosuppressive effects through metabolism of tryptophan to kynurenine. NLG919 affects differentiation and proliferation of T cells by inducing downstream signaling via GCN2, mTOR and AHR, with values of  $K_i = 7$  nM and  $EC_{50} = 75$  nM. NLG919 is being investigated for the treatment of immunosuppression associated with cancer.

**Synonym:** 1-cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethanol

**Appearance:** White powder

**Solubility:** Soluble in DMSO at 15 mg/ml.

**Biological Activity:** NLG919 potently blocks IDO-induced T cell suppression and restored T cell responses with a reported ED<sub>50</sub> of 80 nM *in vitro*. NLG919 reduced the concentration of plasma and tissue kynurenine by ~50% after a single dose in mice. NLG919 enhanced the antitumor responses of naïve, resting pmel-1 T-cells to vaccination with cognate hgp100 peptide plus CpG-1826 in IFA in mice bearing B16F10 tumors.

**Storage/Stability:** Store as supplied at or below -20°C for up to 3 years. Stable in DMSO at -80°C for up to 6 months.

### References:

1. Driessens, G., *et al.*, *J. Immunother. Cancer.* 2014; **2(Suppl 3)**:195.
2. Nayak, A., *et al.* *J. Immunother. Cancer.* 2014; **2(Suppl 3)**: 250.